small molecule

REVLIMID

LENALIDOMIDE

Loss of exclusivityMarch 2028latest FDA-listed patent expiry

CompanyBRISTOL MYERS SQUIBB

Drug detail

Brand name	REVLIMID
Active ingredient	LENALIDOMIDE
Strength	5MG
Dosage form	CAPSULE
Route	ORAL
Modality	Small molecule
FDA approval	December 2005
Marketing status	RX

Listed patents

Patent	Expires	Type
8741929	March 2028	use U-1983
7465800	April 2027	substance, product

Regulatory exclusivity

Code	Expires
ODE-241	May 2026
ODE-245	May 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from BRISTOL MYERS SQUIBB